Ariad Pharmaceuticals Inc. (ARIA) plummeted as much as 43 percent as the company temporarily suspended sales of its only drug Iclusig for patients with certain forms of leukemia. Ariad fell 38 percent to $2.47 at 9:44 a.m. in New York, after plunging to $2.27, the lowest intraday price since February 2010. The U.S. Food and Drug Administration requested the halt yesterday, Cambridge, Massachusetts-based Ariad said today in a statement.